Drug Profile
Hemay 020
Alternative Names: Hemay020Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Hainan General Sanyang Pharmaceutical; Tianjin Hemay Biotech
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer; Solid tumours
Most Recent Events
- 29 Feb 2024 Tianjin Hemay Pharmaceutical and Hainan General Sanyang Pharmaceutical terminates phase I trial in Non-small cell lung cancer (Late-stage disease) in China (PO) (NCT02467569)
- 28 Sep 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease) in China (PO, Capsule)
- 28 Sep 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO, Capsule)